CDL (co-management of diabetes-liver diseases strategy) Literature Review – January 2024, Issue 12

2024.03.12
Diabetes and liver disease are prevalent chronic conditions in China, with interconnections in terms of pathogenesis, clinical manifestations, diagnostic and therapeutic targets, making their combined management essential for alleviating the burden of these diseases. In support of the development of diabetes and liver disease co-management initiatives in China, this publication Hepatology Digest, collaborates with the co-management of diabetes-liver diseases strategy(CDL) to introduce the CDL Literature Review column. Each month, we share literature related to the mechanisms and advancements in the diagnosis and treatment of diabetes-related liver diseases. We also invite experts in the field to provide commentary, aiming to offer insights and assistance to experts, researchers, and frontline healthcare professionals engaged in scientific research and clinical care.

Interpretation of “Chinese Expert Consensus on Immunotherapy for Hepatocellular Carcinoma”

2024.01.12
On December 9-10, 2023, the "Huaxia Shanghai Liver Disease Forum and Shanghai Liver Disease Summit" was successfully held, sponsored by the Huaxia Liver Disease Association, organized by the Shanghai "Liver" Magazine, and co-organized by the Shanghai Medical Association Hepatology Subspecialty Branch, Shanghai Physicians Association Infectious Disease Physicians Branch, Shanghai Infectious Disease Clinical Quality Control Center, and the Long Triangle Representative Office of the China Association of Non-Public Medical Institutions. At the conference, Dr.Xiufeng Liu from the Medical Area of the Qinhuai Hospital of the Eastern Theater General Hospital of the People's Liberation Army provided a detailed interpretation of the "Chinese Expert Consensus on Immunotherapy for Hepatocellular Carcinoma," which was newly issued in China. This journal has invited Dr.Xiufeng Liu to conduct an in-depth interview to introduce the consensus's recommendations regarding first-line and subsequent-line treatment options for liver cancer immunotherapy, as well as the assessment of treatment efficacy and other hot topics. The following content summarizes these insights for readers.
Construction and Validation of a Hepatocellular Carcinoma Prognosis Model Based on Stress Granules

Construction and Validation of a Hepatocellular Carcinoma Prognosis Model Based on Stress Granules

2024.01.08
In an effort to keep clinicians and researchers in the field of hepatology abreast of the latest academic knowledge and research trends, " Hepatology Digest " has collaborated with the "Journal of Clinical and Translational Hepatology" (JCTH) to introduce the "Journal Co-Read" section. Each week, this section selects and interprets highlights from a key publication, summarizing its main points in the hope of enhancing clinical diagnostic and treatment levels, inspiring research thinking, and improving writing skills.